Transgenic mouse models of Alzheimer's disease: Phenotype and application

Behavioural Pharmacology

Volumn 14, Issue 5-6, 2003, Pages 419-438

  Higgins, Guy A ^a   Jacobsen, Heimut ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

amyloid; Alzheimer's disease; Behaviour; Cognition; Mouse models; Tau protein; Transgenic

Indexed keywords

4 [2 [1 (4 CHLOROCINNAMYL) 4 PIPERAZINYL]ETHYL]BENZOIC ACID; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; CLIOQUINOL; CURCAMIN; ENZYME INHIBITOR; ESTER DERIVATIVE; ESTRADIOL; GAMMA SECRETASE INHIBITOR; GANGLIOSIDE GM1; GELSOLIN; IBUPROFEN; LY 411575; N [N (3,5 DIFLUOROPHENACETYL)ALANYL]PHENYLGLYCINE TERT BUTYL ESTER; NCX 2216; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN ANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BEHAVIORAL SCIENCE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOLOGY; GENE IDENTIFICATION; HEREDITY; HUMAN; INFLAMMATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BEHAVIOR, ANIMAL; COGNITION; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; TAU PROTEINS;

EID: 0141596079     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (182)

1. Ahmed SF, Matthews KL, Heslop KE, Marshall VJ, Chapman PF, Francis PT (2001). Biochemical characterisation of GP56 rats transgenic for APPswe: a work in progress. Soc Neurosci Abs 27:965.6.
2. Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, et al. (2002). Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 22:9340-9351.
3. Anderson R, Barnes JC, Bliss TVP, Cain DP, Cambon K, Davies HA, et al. (1998). Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse. Neuroscience 85:93-110.
4. Andra K, Abramowski D, Duke M, Probst A, Wiederhold K-H, Bürkli K, et al. (1996). Expression of APP in transgenic mice: A comparison of neuronspecific promoters. Neurobiol Aging 17:183-190.
5. Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, Diamond DM (2001). Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891:42-53.
6. Arendt T, Holzer M, Fruth R, Bruckner MK, Gartner U (1995). Paired helical filament-like phosphorylation of tau, deposition of β/A4-amyloid and memory impairment in rat induced by chronic inibition of phosphatase 1 and 2A. Neuroscience 69:691-698.
7. Arendt T, Holzer M, Fruth R, Bruckner MK, Gartner U (1998). The use of okadaic acid in vivo and the induction of molecular changes typical for Alzheimer's disease. Neuroscience 85:1337-1340.
8. Bacskai BJ, Kajdask ST, Christie RH, Carter C, Games D, Seubert P, et al. (2001). Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7:369-372.
9. Bales KR, Verina T, Dodel RC, Du Y, Altsteil L, Bender M, et al. (1997). Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 17:263-264.
10. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, et al. (1999). Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 96:15233-15238.
11. Bannerman DM, Good MA, Butcher SP, Ramsey M, Morris RGM (1995). Distinct components of spatial learning revealed by prior training and NMDA receptor blockade. Nature 378:182-186.
12. Bard F, Cannon C, Barbour R, Burke R-L, Games D, Grajeda H, et al. (2000). Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916-919.
13. Bard F, Barbour R, Cannon C, Caretto R, Fox M, Games D, et al. (2003). Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100:2023-2028.
14. Berg L, Morris JC (1994). Diagnosis. In: Terry RD, Katzman R, Bick KL (editors): Alzheimer Disease. New York: Raven Press; pp. 197-229.
15. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, et al. (2000). Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290:2302-2323.
16. Boncristiano S, Calhoun ME, Kelly PH, Pfeifer M, Bondolfi L, Stadler M, et al. (2002). J Neurosci 22:3234-3243.
17. Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold K-H, Walker L, et al. (2002). Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci 22:515-522.
18. Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovtisky T, et al. (1996). A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal: Biomol Engin 13:159-163.
19. Borchelt DR, Ratovitski T, Van Lare J, Lee MK, Gonzales V, Jenkins NA, et al. (1997). Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19:939-945.
20. Braak H, Braak E (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82:239-259.
21. Bush AI, Pettingell WH, Multhaup G, Paradis M, Vonsattel J-P, Gusella JF, et al. (1994). Rapid induction of Alzheimer Abeta amyloid formation by zinc. Science 265:1464-1467.
22. Calhoun ME, Wiederhold K-H, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, et al. (1998). Neuron loss in APP transgenic mice. Nature 395:755-756.
23. Carlson GA, Borchelt DR, Dake A, Turner S, Danielson V, Coffin JD, et al. (1997). Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum Mol Genet 6:1951-1959.
24. Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, et al. (1999). Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2:271-276.
25. Check E (2002). Nerve inflammation halts trial for Alzheimer's drug. Nature 415:462.
26. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, et al. (2000). A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408:975-979.
27. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. (2001). Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676.
28. Chishti MA, Yang D-S, Janus C, Phinney AL, Horne P, Pearson J, et al. (2001). Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276:21562-21570.
29. Christie RH, Bacskai BJ, Zipfel WR, Williams RM, Kajdasz ST, Webb WW, Hyman BT (2001). Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in-vivo multiphoton microscopy. J Neurosci 21:858-864.
30. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
31. Crawley JN, Paylor R (1997). A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav 31:197-211.
32. Crawley JN, Belknapp JK, Collins A, Crabbe JC, Frankel W, Henderson N, et al. (1997). Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 132:107-124.
33. Cummings BJ, Cotman CW (1995). Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet 346:1524-1528.
34. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE (2001). Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 22:721-727.
35. Das P, Chapoval S, Howard V, David CS, Golde TE (2003). Immune responses against Aβ1-42 in HLA class II transgenic mice: implications for Aβ1-42 immune-mediated therapies. Neurobiol Aging (in press).
36. DeMattos RB, Bales KR, Cummins DJ, Dodart J-C, Paul SM, Holtzman DM (2001). Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855.
37. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM (2002). Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295:2264-2267.
38. DeStrooper B (2003). Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron 38:9-12.
39. DeStrooper B, Woodgett J (2003). Mental plaque removal. Nature 423:392-393.
40. DeStrooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. (1998). Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391:387-390.
41. Dodart J-C, Meziane H, Mathis C, Bales KR, Paul SM, Ungerer A (1999). Behavioral disturbances in transgenic mice overexpressing the V717F β-amyloid precursor protein. Behav Neurosci 113:982-990.
42. Dodart J-C, Mathis C, Saura J, Bales KR, Paul SM, Ungerer A (2000). Neuroanatomical abnormalities in behaviorally characterized APPV717F transgenic mice. Neurobiol Dis 7:71-85.
43. Dodart J-C, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. (2002). Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 5:452-457.
44. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, et al. (2001). Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in-vivo. J Neurochem 76:173-181.
45. Duff K, Eckman C, Zehr C, Yu X, Prada C-H, Perez-Tur J, et al. (1996). Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 383:710-713.
46. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, et al. (2000). Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 290:2303-2304.
47. Everitt BJ, Robbins TW (1997). Central cholinergic systems and cognition. Annu Rev Psychol 48:649-684.
48. Fagan AM, Watson M, Paradanian M, Bales KR, Paul SM, Holtzman DM (2002). Human and murine ApoE markedly alters Aβ metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 9:305-318.
49. Fitzjohn SM, Morton RA, Kuenzi F, Rosahl TW, Shearman M, Lewis H, et al. (2001). Age-related impairment of synaptic transmission but normal longterm potentiation in transgenic mice that overexpress the human APP695swe mutant form of amyloid precursor protein. J Neurosci 21:4691-4698.
50. Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, et al. (2003). Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the Biological Markers Working Group: NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 24:521-536.
51. Games D, Khan KM, Soriano FG, Keim PS, Davis DL, Bryant K, Lieberburg I (1992). Lack of Alzheimer pathology after β-amyloid protein injections in rat brain. Neurobiol Aging 13:569-576.
52. Games D, Adams D, Alessandrini R, Barbous R, Berthelette P, Blackwell C, et al. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373:523-527.
53. Gauthier S (1999). Acetylcholinesterase inhibitors in the treatment of Alzheimer's disease. Exp Opin Invest Drugs 8:1511-1520.
54. Gerlai R, Fitch T, Bales KR, Gitter BD (2002). Behavioral impairment of APPV717F mice in fear conditioning: is it only cognition? Behav Brain Res 136:503-509.
55. Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, et al. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704-706.
56. Goetz J, Chen F, Barmettler R, Nitsch RM (2001a). Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276:529-534.
57. Goetz J, Chen F, Van Dorpe J, Nitsch RM (2001b). Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science 293:1491-1495.
58. Gomez-Isla T, Price JL, McKeel DW, Morris JC, Growden JH, Hyman BT (1996). Profound loss of layer II entorhinal codex neurons occurs in very mild Alzheimer's disease. J Neurosci 16:4491-4500.
59. Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, et al. (2001). Correlation between cognitive deficits and Aβ deposits in transgenic APP + PS1 mice. Neurobiol Aging 22:377-386.
60. Haass C (2002). New hope for Alzheimer disease vaccine. Nat Med 8:1195-1196.
61. Hadland BK, Manley NR, Su D, Longmore GD, Moore CL, Wolfe MS, et al. (2001). Gamma-secretase inhibitors repress thymocyte development. Proc Natl Acad Sci USA 98:7467-7491.
62. Hagan JJ (1994). The status of the cholinergic hypothesis of dementia. In: Anti-Dementia Agents. London: Academic Press; pp. 65-138.
63. Hardy J, Allsop D (1991). Amyloid deposition as the central event in the aetiology of Aizheimer's disease. Trends Pharmacol Sci 12:383-388.
64. Hardy J, Selkoe DJ (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
65. Hartman RE, Wozniak DF, Nardi A, Olney JW, Sartorius L, Holtzman DM (2001). Behavioral phenotyping of GFAP-ApoE3 and -ApoE4 transgenic mice: ApoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology. Exp Neurol 170:326-344.
66. Hartman RE, Laurer H, Longhi L, Bales KR, Paul SM, McIntosh TK, Holtzman DM (2002). Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. J Neurosci 22:10083-10087.
67. Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B (2000). Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol 2:461-462.
68. Higgins LS, Holtzman DM, Rabin J, Mobley WC, Cordell B (1994). Transgenic mouse brain histopathology resembles early Alzheimer's Disease. Ann Neurol 35:598-607.
69. Higgins LS, Rodems JM, Catalano R, Quon D, Cordell B (1995). Early Alzheimer disease-like histopathology increases in frequency with age in mice transgenic for β-APP751. Proc Natl Acad Sci USA 92:4402-4406.
70. Higgins GA, Enderlin M, Fimbel R, Haman M, Grottick AJ, Soriano M, et al. (2002). Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia. Eur J Neurosci 15:1827-1840.
71. Higuchi M, Ishihara T, Zhang B, Hong M, Andreadis A, Trojanowski JQ, Lee VM-Y (2002). Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration. Neuron 35:433-446.
72. Hock BJ, Lamb BT (2001). Transgenic mouse models of Alzheimer's disease. Trends Genet 17:S7-S12.
73. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, et al. (2003). Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38:547-554.
74. Hof PR, Morrison JH (1994). The cellular basis of cortical disconnection in Alzheimer Disease and related dementing conditions. In: Terry RD, Katzman R, Bick KL (editors): Alzheimer Disease. New York: Raven Press; pp. 197-229.
75. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. (1998). Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97-100.
76. Holcomb L, Gordon MN, Jantzen P, Hsaio K, Duff K, Morgan D (1999). Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet 29:177-185.
77. Hsaio K, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, et al. (1995). Age related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15:1203-1216.
78. Hsaio K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. (1996). Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
79. Hsaio K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. (1997). Response to: Routtenberg A, Commentary: Measuring memory in a mouse model of Alzheimer's disease. Science 277:840-841.
80. Huitron-Resendiz S, Sanchez-Alavez M, Gallegos R, Berg G, Crawford E, Giacchino JL, et al. (2002). Age-independent and age-related deficits in visuospatial learning, sleep-wake states, thermoregulation and motor activity in PDAPP mice. Brain Res 928:126-137.
81. Hyde LA, Kazdoba TM, Higgins GA (2003). Age-related spatial Morris water maze impairments in transgenic CRND8 mice expressing a double mutant form of amyloid precursor protein. Soc Neurosci Abs (in press).
82. Irizarry MC, McNamara M, Fedorchak K, Hsaio K, Hyman BT (1997a). APPsw transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropath Exp Neurol 56:965-973.
83. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT (1997b). Aβ deposition is associated with neurophil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17:7053-7059.
84. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, et al. (2002). Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing non-steroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22:2246-2254.
85. Janus C, Pearson J, McLaurin J, Matthews PM, Jiang Y, Schmidt SD, et al. (2000). Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982.
86. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, et al. (1997). Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 94:1550-1555.
87. Jolas T, Zhang X-S, Zhang Q, Wong G, Del Vecchio R, et al. (2002). Long term potentiation is increased in the CA1 area of the hippocampus of APPswe/ind CRND8 mice. Neurobiol Dis 11:394-409.
88. Kalback WM, Watson MD, Kokjohn TA, Kuo Y, Weiss N, Luehrs DC, et al. (2002). APP transgenic mice Tg2576 accumulate Aβ peptides distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 41:922-928.
89. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001). Age-dependent changes in brain, csf, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21:372-381.
90. Kelly PH, Bondolfi L, Hunziker D, Schlecht H-P, Carver K, Maguire E, et al. (2003). Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging 24:365-378.
91. King DL, Arendash GW, Crawford F, Sterk T, Menendez MJ, Mullan MJ (1999). Progressive and gender dependent cognitive impairment in the APPswe transgenic mouse model of Alzheimer's disease. Behav Brain Res 103:145-162.
92. Kirkby DL, Higgins GA (1998). Characterization of perforant path lesions in rodent models of memory and attention. Eur J Neurosci 10:823-838.
93. Kirkby DL, Jones DNC, Barnes JC, Higgins GA (1996). Effects of anticholinesterase drugs tacrine and E2020, the 5-HT3 antagonist ondansetron, and the H3 antagonist thioperamide, in models of cognition and cholinergic function. Behav Pharmacol 7:513-525.
94. Klein WL, Krafft GA, Finch CE (2001). Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? TINS 24:219-224.
95. Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, et al. (2001). Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbour diffuse β-amyloid deposits but do not form plaques. Proc Natl Acad Sci USA 98:14675-14680.
96. Kosik K, Coleman P (1992). Special issue Neurobiology Aging: Is β-amyloid neurotoxic? Neurobiol Aging 13:535-627.
97. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, et al. (2002). Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22:6331-6335.
98. Kulnane LS, Lamb BT (2001). Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol Dis 8:982-992.
99. Kung M-P, Hou C, Zhuang Z-P, Zhang B, Skovronsky D, Trojanowski JQ, et al. (2002). IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques. Brain Res 956:202-210.
100. Kuo Y, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JZ, et al. (2001). Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 276:12991-12998.
101. Lalonde R, Domont M, Staufenbiel M, Sturchler-Pierrat C, Strazielle C (2002). Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with Swedish mutation. Brain Res 956:36-44.
102. Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, Merchant K (2003). The γ-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces Aβ levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 305:864-871.
103. Lazarov O, Lee M, Peterson DA, Sisodia SS (2002). Evidence that synaptically released β-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 22:9785-9793.
104. Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM (2002). Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Aβ peptide radio-pharmaceutical. J Cereb Blood Flow Metab 22:223-231.
105. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell H, et al. (1995). Candidate gene on chromosome 1 familial Alzheimer's disease locus. Science 269:973-977.
106. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, et al. (2000). Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25:402-405.
107. Lewis J, Dickson DW, Lin W-L, Chisholm L, Corral A, Jones G, et al. (2001). Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-1491.
108. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, et al. (2000). Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20:5709-5714.
109. Lim GP, Chu T, Yang F, Beech W, Frautschy SA. Cole GM (2001). The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21:8370-8377.
110. Lippa CF, Fujiwara H, Mann DMA, Giasson B, Baba M, Schmidt ML, et al. (1998). Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153:1365-1370.
111. Logue SF, Paylor R, Wehner JM (1997). Hippocampal lesions cause learning deficits in inbred mice in the Morris water maze and conditioned fear task. Behav Neurosci 111:104-113.
112. Marx J (1992). News and Comment: Major setback for Alzheimer's models. Science 255:1200-1202.
113. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D (1996). Comparison of neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease. J Neurosci 16:5795-5811.
114. Mathis CA, Bacskai BJ, Kaidasz ST, McLellan ME, Frosch MP, Hyman BT, et al. (2002). A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12:295-298.
115. Matsuoka Y, Picciano M, La Francois J, Duff K (2001). Fibrillar β-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience 104:609-613.
116. Matsuoka Y, Saito M, La Francois J, Saito M, Gaynor K, et al. (2003). Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J Neurosci 23:29-33.
117. May PC, Altstiel L, Bender MH, Boggs LN, Calligaro DO, Fuson KS, et al. (2001). Marked reduction of Aβ accumulation and β-amyloid plaque pathology in mice upon chronic treatment with a functional gamma-secretase inhibitor. Soc Neurosci Abs 27:687.1.
118. Mayeux R, Ottman R, Maestre G, Ngai C, Tang MX, Ginsberg H, et al. (1995). Synergistic effects of traumatic head injury and apolipoprotein-E4 in patients with Alzheimer's Disease. Neurology 45:555-557.
119. McGowan E, Sanders S, Iwatsubo T, Takeuchi A, Saido T, Zehr C, et al. (1999). Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 6:231-244.
120. Mohajeri MH, Saini K, Schultz JG, Wollmer MA, Hock C, Nitsch RM (2002). Passive immunization against β-amyloid peptide protects CNS neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 277:33012-33017.
121. Moran PM, Higgins LS, Cordell B, Moser PC (1995). Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human β-amyloid precursor protein. Proc Natl Acad Sci USA 92:5341-5345.
122. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. (2000). Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-986.
123. Morris JC, Price AL (2001). Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 17:101-118.
124. Mucke L, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, et al. (1994). Synaptotrophic effects of human amyloid β protein precursors in the codex of transgenic mice. Brain Res 666:151-167.
125. Mudher AK, Lovestone S (2002). Alzheimer's disease - do tauists and baptists finally shake hands? Trends Neurosci 25:22-26.
126. Mudher AK, Perry VH (1998). Using okadaic acid as a tool for the in vivo induction of hyperphosphorylated tau, Neuroscience 85:1329-1332.
127. Mullan M, Crawford F, Houlden H, Axelman K, Lilius L, Winblad B, Lannfeldt L (1992). A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nat Genet 1:345-347.
128. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, et al. (2000). Susceptibility locus for Alzheimer's disease on chromosome 10. Science 290:2304-2305.
129. Myhrer T (1993). Animal models of Alzheimer's disease: glutamatergic denervation as an alternative to cholinergic denervation. Neurosci Biobehav Rev 17:195-202.
130. Nicoll JAR, Roberts GW, Graham DI (1995). Apolipoprotein E4 allele is associated with deposition of amyloid β-protein following head injury. Nat Med 1:135-137.
131. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 9:448-452.
132. Nordberg A, Hellstrom-Lindahl E, Lee M, Johnson M, Mousavi M, et al. (2002). Chronic nicotine treatment reduces β-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPswe). J Neurochem 81:655-658.
133. Orgogozo J-M, Gilman S, Dartigues J-F, Laurent B, Puel M, Kirby LC, et al. (2003). Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61:46-54.
134. Owen EH, Logue SF, Rasmussen DL, Wehner JM (1997). Assessment of learning by the Morris water task and fear conditioning in inbred mouse strains and F1 hybrids: implications of genetic background for single gene mutations and quantitative trait loci analyses. Neuroscience 80:1087-1099.
135. Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, et al. (2001). Correlation between Aβx-40-, Aβx-42-, and Aβx-43-containing amyloid plaques and cognitive decline. Arch Neurol 58:2025-2032.
136. Pfeifer M, Boncristiano S, Bondolfi L, Stadler A, Deller T, et al. (2002). Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 298:1379.
137. Phiel CJ, Wilson CA, Lee VM-Y, Klein PS (2003). GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 423:435-439.
138. Podlisky MB, Stephenson DT, Frosch MP, Lieberburg I, Clemens JA, Selkoe DJ (1992). Synthetic amyloid β-protein fails to produce specific neurotoxicity in monkey cerebral cortex. Neurobiol Aging 13:561-567.
139. Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, et al. (2002). Molecular targetting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 11:315-329.
140. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM (2001). Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21:4183-4187.
141. Price DL, Sisodia SS, Borchelt DR (1998). Genetic neurodegenerative diseases: the human illness and transgenic models. Science 282:1079-1083.
142. Quon D, Wang Y, Catalano R, Scardina JM, Murkami K, Cordell B (1991). Formation of β-amyloid protein deposits in brains of transgenic mice. Nature 352:239-241.
143. Redwine JM, Kosofsky B, Jacobs RE, Games D, Reilly JF, Morrison JH, et al. (2003). Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: A magnetic resonance microscopy and stereologic analysis. Proc Natl Acad Sci USA 100:1381-1386.
144. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, et al. (2001). A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8:890-899.
145. Reilly JF, Games D, Rydel RE, Freedman S, Schenk D, Young WG, et al. (2003). Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. Proc Natl Acad Sci USA 100:4837-4842.
146. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003). Memantine in moderate-to-severe Alzheimer's Disease. N Engl J Med 348:1333-1341.
147. Richards JG, Messer J, Goepfert F, Ozmen L, Brockhaus M, Bohrman B, et al. (2001). Double transgenic mice, overexpressing hAPPswe and hPS2mut show age-dependant cognitive deficits, and amyloid deposits in discrete brain regions. Soc Neurosci Abs 27:546.7.
148. Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew J NC, Bohrmann B, et al. (2003). PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci (in press).
149. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, et al. (2001). BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 10:1317-1324.
150. Routtenberg A (1997). Commentary: Measuring memory in a mouse model of Alzheimer's disease. Science 277:839-840.
151. Schauwecker PE, Steward O (1997). Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc Natl Acad Sci USA 94:4103-4108.
152. Schenk D (2002). Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3:824-828.
153. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda T, Guido T, et al. (1999). Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
154. Selkoe DJ (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
155. Sheng JG, Price DL, Koliatsos VE (2002). Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Aβ amyloidosis. J Neurosci 22:9794-9799.
156. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375:754-760.
157. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T (2001). Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's Disease-associated pathology in transgenic mice. Am J Pathol 159:439-447.
158. Sisodia SS, St. George-Hyslop PH (2002). γ-Secretase, notch, Aβ and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 3:281-290.
159. Skovronsky DM, Zhang B, Kung M-P, Kung HF, Trojanowski JQ, Lee VM-Y (2000). In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97:7609-7614.
160. Smith G (1988). Animal models of Alzheimer's disease: experimental cholinergic denervation. Brain Res Rev 13:103-118.
161. Smith MA, Hirai K, Hsaio K, Pappolla MA, Harris PLR, Siedlak SL, et al. (1998). Amyloid-β deposition in Alzheimer transgenic mice is associated
162. Stein TD, Johnson JA (2002). Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 22:7380-7388.
163. Steward O, Schauwecker PE, Guth L, Zhang Z, Fujiki M, Inman D, et al. (1999). Genetic approaches to neurotrauma research: opportunities and potential pitfalls of murine models. Exp Neurol 157:19-42.
164. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold K-H, Mistl C, et al. (1997). Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94: 13287-13292.
165. Takeuchi A, Irizarry MC, Duff K, Saido TC, Hsaio Ashe K, et al. (2000). Age-related amyloid β deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid β precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol 157: 331-339.
166. Urbanc B, Cruz L, Le R, Sanders J, Hsaio Ashe K, et al. (2002). Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc Natl Acad Sci USA 99:13990-13995.
167. Van Dam A-M, Bol JGJM, Binnekade R, Van Muiswinkel FL (1998). Acute or chronic administration of okadaic acid to rats induces brain damage rather than Alzheimer-like neuropathology. Neuroscience 85:1333-1335.
168. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP (2003). Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 17:388-396.
169. Van Hoesen GW, Hyman BT, Damasio AR (1991). Entorhinal cortex pathology in Alzheimer's disease. Hippocampus 1:1-8.
170. Vassar R, Citron M (2000). Aβ-generating enzymes: recent advances in β- and γ-secretase research. Neuron 27:419-422.
171. Vitiello MV, Bliwise DL, Prinz PN (1992). Sleep in Alzheimer's disease and the sundown syndrome. Neurology 42:83-93.
172. Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A (2001). Sundowning and circadian rhythms in Alzheimer's disease. Am J Psychiatry 158:704-711.
173. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539.
174. Wengenack TM, Whelan S, Curran GL, Duff KE, Puduslo JF (2000). Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience 101:939-944.
175. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, et al. (2002). The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22:1858-1867.
176. Willner P (1991). Behavioural models in psychopharmacology. In: Willner P (editor): Behavioural Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives.: Cambridge University Press; pp. 3-18.
177. Winblad B, Blum KI (2003). Hints of a therapeutic vaccine for Alzheimer's? Neuron 38:517-518.
178. Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold K-H, et al. (2001). Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 21:1619-1627.
179. Wong GT, Zhang Q, Manfra D, Engstrom L, Pinzon-Ortiz MC, Fine J et al. (2003). Chronic treatment with the γ-secretase inhibitor LY411575 inhibits Aβ production and alters hematopoiesis in vivo (in preparation).
180. Wong PC, Cai H, Borchelt DR, Price DL (2002). Genetically engineered mouse models of neurodegenerative diseases. Nat Neurosci 5:633-639.
181. Yang F, Ueda K, Chen P-P, Ashe KH, Cole GM (2000). Plaque-associated α-synuclein (NACP) pathology in aged transgenic mice overexpressing amyloid precursor protein. Brain Res 853:381-383.
182. Zheng H, Xu H, Uljon SN, Gross R, Hardy K, et al. (2002). Modulation of Aβ peptides by estrogen in mouse models. J Neurochem 80:191-196.